FUZHOU, China, Aug. 29, 2025 /PRNewswire/ — E-Home Household Service Holdings Limited (NASDAQ:EJH) (the “Company” or “eHome”), an integrated home services provider in China, has announced the launch of AI-powered home cleaning robots. The aim is to gradually replace manual cleaning services with robotic solutions.

As the pace of life accelerates and the demand for a better quality of life increases, the demand for domestic services continues to grow. AI-powered home cleaning robots are gradually changing our perception of cleaning the home. The gradual replacement of manual cleaning with convenient, efficient and intelligent AI home cleaning robots will undoubtedly become the norm in the domestic service industry of the future. Using modern technology to improve service quality and optimise the allocation of human resources will speed up the domestic service industry’s transition towards automation.

Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: “E-Home has introduced AI cleaning robots into household cleaning services, aiming to gradually replace manual labor with robotic solutions. This approach significantly saves time and effort while greatly enhancing the customer experience. It reduces operational costs for businesses and opens up broader development prospects for the company.”

About E-Home Household Service Holdings Limited

Established in 2014, E-Home Household Service Holdings Limited is a Nasdaq-listed household service company based in Fuzhou, China.

The company is mainly involved in: 1. Home appliances, smart home installation, maintenance; 2. Housekeeping, cleaning and babysitting services; 3. Home care; 4. Units of public places cleaning; 5. Chuangying: presidential training, internal training, corporate consulting and counseling, and policy counseling.

The company has realized Internet + AI in operation and management: 1. Customer service has been worked by AI customer service; 2. Management has realized Internet + AI; 3. AI robots have been introduced to pilot cleaning staff.

After years of development, E-Home has been a comprehensive service enterprise for family life! We have always adhered to the “solving every issue of customers with heart” business philosophy, adhere to do the industry benchmark. For more information, visit the Company’s website at http://www.ej111.com/ir.html. 

Forward-Looking Statement

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors.

HONG KONG, Aug. 29, 2025 /PRNewswire/ — On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company’s 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position.

The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEO Chen Qiyu, Co-CEO Xu Xiaoliang, CFO Gong Ping, along with numerous investors and analysts.

Guo Guangchang highlighted that Fosun achieved significant breakthroughs across several business segments in the first half of 2025, particularly in the biopharmaceutical segment. Moving forward, Fosun will seize growth opportunities and aim for breakthrough progress through technology innovation.

Regarding investor concerns about innovative drug R&D, Guo Guangchang explained that within Fosun’s robust pipeline, it has reserved a batch of important products. Fosun’s pharmaceutical innovation will extend beyond just Henlius. It also has Fosun Kite’s CAR-T therapy, along with innovative drugs from its established product divisions, all of which have immense potential.

Guo Guangchang said, “I have been emphasizing to our team that we shouldn’t just sell off all our innovative drugs. Both licensing in and licensing out are important. Some products may command a high price if simply licensed out, but we are not in a rush. We should continue to advance our R&D to make these products the best in the world.”

Guo Guangchang said that Fosun previously stated its vision is to help everyone to live healthily and happily to the age of 121. In particular, Fosun’s self-imposed goal is that cancer should be curable. With the current trajectory of pharmaceuticals development, this increasingly feels like an achievable reality. Many cancers today are already preventable, treatable, detectable, curable, or can be managed as chronic, controllable conditions.

Guo Guangchang believes that future cancer treatment will not rely on a single approach, it will involve a combination of approaches, including drugs, devices, and multi-molecule therapies, similar to a cocktail therapy. Fosun possesses a distinct advantage in these areas due to its comprehensive strategic layout and broad industry presence in the Health segment. Future cancer treatment will require comprehensive capability, and this comprehensive capability is precisely one of Fosun Pharma’s hallmark characteristics.

He emphasized that what sets Fosun apart from other Chinese pharmaceutical companies is Fosun’s commitment to building its own global R&D capabilities, global clinical capabilities, and global sales capabilities. This is Fosun’s unwavering mission—and the fundamental path for it to become a truly global pharmaceutical leader.

When sharing his insights on building a business, Guo Guangchang said that nowadays, it is very difficult to establish true competitive strength without at least a decade or two of effort. For example, Henlius, now 15 years old, saw its initial 10-plus years involve investments exceeding RMB10 billion with virtually no returns; it was all about long-term investment. Fosun’s two domestic insurance companies, Fosun United Health Insurance and Pramerica Fosun Life Insurance, one founded 8 years ago and the other 13 years ago, are now entering a period of comprehensive profitability.

He stated that Fosun’s excitement doesn’t lie in new sectors; it lies in deepening and thoroughly developing industries that it has established significant industry advantages, striving to achieve breakthroughs, accelerate growth, and ascend to the pinnacle within these mature sectors, securing a commanding global position.

Guo Guangchang said, “Even old wine needs innovation. Fosun’s Shede Spirits has recently conducted innovative R&D on high-alcohol traditional baijiu and launched a new liquor with 29% ABV, named ‘Shede Zizai’, meaning ‘Shede at Ease’. It retains the flavor of aged liquor while meeting today’s younger generation’s pursuit of health.”

SHANGHAI, Aug. 29, 2025 /PRNewswire/ — United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first half of 2025, maintaining steady growth. The company’s revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit or loss reached CNY 6.02 billion and 0.97 billion for 2025H1, representing a year-over-year increase of 12.79% and 21.01% respectively.

The company’s revenue growth was primarily fueled by continuous launch of innovative high-end products, now widely recognized in the market, alongside the expansion in overseas markets and the growth of service revenues. In the first half of 2025, overseas revenue reached CNY 1.14 billion and service revenue reached CNY 0.82 billion, accounting for 18.99% and 13.56% of total revenue respectively, both reaching record highs.

R&D investment plays a pivotal role in driving innovation. In the first half of 2025, United Imaging Healthcare’s R&D investment reached CNY 1.14 billion, representing a year-over-year increase of 12.09%, primarily allocated to next-generation platform technology and innovations in core products.

As of the date of this report, the company had introduced over 140 innovative products globally, of which 53 were cleared by the U.S. FDA through the 510(k) process and 57 were CE certified under MDR/MDD. The company is accelerating the commercial deployment of its AI-enabled products, with FDA-authorized AI medical equipment exceeding 20, including uCT ATLAS Astound, uMI Panorama, uMI Panvivo, uMR Jupiter, uMR Omega and uMR 680.

Multiple globally impactful products were launched in the first half of the year. uMR Ultra enables high-clarity soft-tissue diagnostics through real-time high-definition imaging. uCT SiriuX (not yet cleared or approved by the FDA or CE marked for commercial use) provides a proprietary dual-wide gantry architecture. uAngio AVIVA received FDA clearance, featuring industry-first intelligent voice-assist technology for hands-free operation during procedures.

The global medical equipment industry continues to expand. The company’s overseas orders maintained robust growth particularly in premium and innovative products during the first half of 2025.

In North America, United Imaging Healthcare’s premium imaging equipment have covered over 70% of U.S. states, accumulating more than 400 installations by the end of 2025H1.

In Europe, United Imaging Healthcare has successfully delivered a significant number of high-end medical equipment and established a strong market presence in over 20 countries, including UK, Germany, Italy, France, Spain, Ukraine, Poland, Greece, Romania, and Hungary.

In Asia-Pacific and Latin America, United Imaging Healthcare achieved key breakthroughs and landmark installations. Notably, the company secured a major account and deployed systems at Singapore General Hospital, which is ranked first in Asia and ninth worldwide.

Looking ahead, United Imaging Healthcare will continue to expand its global presence, accelerating the delivery of premium medical equipment. At the same time, the company will strengthen its AI innovation to drive the intelligent and precision transformation of medical imaging equipment, providing more efficient and accurate solutions for the global healthcare industry.

JIUJIANG, China, Aug. 29, 2025 /PRNewswire/ — On 29 August, “JIUJIANG: THE ESSENCE OF CHINESE LANDSCAPES” 2025 Jiujiang Cultural & Tourism Singapore Roadshow took place at Orchard Hotel. Present were Wang Jianxin, Party Secretary & Director of Jiujiang Municipal Bureau of Culture, Radio, TV and Tourism; Shi Lan, Party Secretary & Director of Jiujiang Municipal Commerce Bureau; Xiao Fangmin, President of the National Association of Travel Agents Singapore (NATAS); Kuang Rongfa, Director of Lushan Municipal Bureau; Wu Shuguang, Director of Lushan West Sea Bureau; Deng Feng, Party Secretary of Yongxiu County Bureau; and over 100 representatives from scenic spots, travel agencies and media of both sides.

In his address, Wang Jianxin noted that Singapore and Jiujiang, both thriving on water and commerce, share time-honoured ties. Jiujiang Party Secretary Liu Wenhua has led several delegations to Singapore, while the Singapore Consul-General in Xiamen has praised Jiujiang’s location and business climate. He invited Singapore visitors to fly direct to Nanchang Changbei Airport and “start from Singapore, relax in Xunyang”.

Xiao Fangmin responded by pledging deeper two-way visitor exchanges.

During the presentations, Kuang Rongfa showcased the UNESCO World Cultural Landscape of Lushan through five “Yōu” themes (history, culture, scenery, lifestyle and serenity). Wu Shuguang unveiled Lushan West Sea’s thousand-island vistas, wellness retreats, water sports and intangible-heritage experiences. Deng Feng highlighted Yongxiu’s Poyang Lake wetlands—”painted lakes and a kingdom of migratory birds”. A bespoke Jiujiang itinerary video for the Singapore market premiered simultaneously.

Duck & Tour (Singapore) signed with Jiangxi Yuanda International Travel, and Hong Thai Travel (Singapore) with China Travel Service Jiujiang. The agreements mark Jiujiang’s deeper entry into the Southeast Asian market and lay a solid foundation for Belt-and-Road win-win tourism cooperation.